Goodwin is pleased to invite you to our Life Sciences Disputes webinar series, which will highlight current topics across our Securities Litigation and Antitrust practice areas that affect life sciences companies.
Trends and Hot Topics in Securities Litigation and SEC Enforcement for the Life Sciences Industry
November 9, 2021 – 1:00 pm – 2:00 pm EST
Life sciences and biotech companies are particularly vulnerable to securities class actions due to the variety of event-driven disclosures and the inherently volatile nature of their stock prices. Because of this, over the past several years the biotech and life sciences industries have been the most targeted industries by plaintiffs’ lawyers and a consistent focus of the SEC. Our panel will address the unique securities law disclosure issues facing life sciences companies, particularly with respect to managing risk arising from disclosures of clinical trial results and communications with FDA.
FTC Antitrust Lessons Learned for Life Sciences Companies
November 18, 2021 – 2:00 pm – 3:00 pm EST
Over the past several months, Federal Trade Commission (FTC) oversight has been unprecedently high when it comes to exit transactions. Additionally, rules are changing in real time that affect M&A transactions and licensing collaborations, especially in the life sciences industry.